Adherence therapy for medication non-compliant XXXX with @entity101 : a randomised controlled trial.

@entity1 @entity5624 @entity101 @entity34
The objective of this study is to establish the efficacy of @entity34 ( @entity34 ) compared with treatment as usual (TAU) in reducing blood pressure (BP) in non-compliant @entity101 @entity1 . This study was designed as a parallel-group single-blind randomised controlled trial. The study was carried out at three general hospital outpatient clinics in Jordan. A total of 136 non-compliant @entity101 @entity1 with a mean baseline BP of 164.5   mm   Hg (s.d. 10.0) over 102.2   mm   Hg (s.d. 7.0) participated in the study. 7 weekly 20-min sessions of @entity34 in addition to TAU. The main outcome of this study is systolic blood pressure (SBP) at 11-weeks follow-up. In all, 68 @entity1 received TAU and 68 @entity34 . Intention-to-treat analysis included all @entity1 randomised. @entity34 lowered SBP by -23.11   mm   Hg (95% CI: -25.85, -20.36) and diastolic BP (DBP) by -15.18   mm   Hg (95% CI: -17.55, -12.80) at 11 weeks compared with TAU. Adherence (measured by pill counting) was also improved in the @entity34 group by 37% at 11 weeks compared with @entity5624 . No significant adverse events were reported. @entity34 increases adherence to medication for @entity101 which then leads to a clinically important reduction in BP.
